ERBB2 and neoplasm: In addition to mAbs, peptide–drug conjugates (PDCs) with lengths of less than 20 amino acids have been found to improve tumor targeting through the recognition of proteins that are overexpressed on tumor cell surfaces (erbB2, VEGF receptor, αVβ3 integrin, etc.)[4].